Scientists developed adenine base editing to correct a genetic mutation causing hereditary motor neuron disease. The therapy successfully alleviated neurodegeneration in a mouse model and patient-derived organoids, offering hope for precision gene therapies to address neurodegenerative diseases.
Researchers discovered PRDM16 acts as a developmental 'rheostat' guiding cardiomyocytes toward functional competence. The study reveals moderate PRDM16 overexpression promotes maturation while suppressing proliferation, offering opportunities for regenerative responses.
Scientists have successfully transplanted human stem cells into monkeys with Parkinson's disease, showing long-term benefits. The quality of donor cells, particularly the Dlk1 gene, played a crucial role in determining cell survival. This study brings iPS cell-based therapy closer to clinical trials.
Researchers found that the expression of specific genes and DNA methylation patterns, such as IFG2 and reduced aberrant methylation, are better indicators of iPS cell differentiation to hematopoietic cells. This discovery suggests a more efficient method for producing high-quality blood cells through reprogramming.
Researchers at Kyoto University's Yamada lab created a mouse model to study the EWS-FLI1 gene's role in bone cancer. The model revealed that other mutations are necessary for cancer development and that correcting osteogenic cell differentiation could prevent bone cancers.
Researchers found that diseased exocrine tissue can cause deficiencies in endocrine cells, leading to diabetes. The discovery suggests a new target for stem cell-based treatments.
Japanese researchers used iPS cell technology to increase the number of invariant natural killer T (iNKT) cells, which are rare helper immune cells that can activate cytotoxic cells against cancer. The creation of potent iNKT cells has important implications for understanding immune cell formation and developing new cancer therapies.
Researchers at Kyoto University discovered that heart cells differentiated from induced pluripotent stem (iPS) cells can be used to treat damaged hearts. The study found an optimal maturation stage for heart cells, which is crucial for improving patient outcomes and reducing the number of cells required for therapy.
Researchers found Activin-A as a candidate drug target for treating Fibrodysplasia ossificans progressive (FOP), a genetic disease where bone grows in soft tissue. The study uses induced pluripotent stem cells and suggests that inflammation could be the key to preventing diseased bone growth.
Researchers have designed a model that reprograms fibroblasts to study Duchenne muscular dystrophy development using induced pluripotent stem cells. The study reveals that calcium ion channels may cause muscle degeneration in DMD patients, providing a clear drug target for treatment.
Researchers used iPSC-derived renal progenitors to treat acute kidney injury in mice, showing improved recovery with reduced fibrosis and necrosis. The study's findings suggest that paracrine actions of the cells, rather than integration, led to therapeutic effects.
Researchers have developed a new technology that uses synthetic microRNA switches to purify live human cells with improved efficiency. The method, which involves identifying unique miRNAs for each cell type, shows promise for clinical applications and could lead to more homogeneous cell pools and better cell therapy outcomes.
Researchers have found that the length of Klf4 mRNA affects iPS cell reprogramming, with shorter forms leading to incomplete reprogramming. Longer forms result in more complete reprogramming and higher protein expression levels.
Researchers have developed a scaffold-free method to generate hyaline cartilage from iPS cells, offering a promising alternative to traditional autologous chondrocyte transplantation. The new protocol avoids fibrous tissue formation and allows for the direct transplantation of chondrocytes with high purity.
Researchers used iPS cells to correct genetic mutations in Duchenne muscular dystrophy (DMD), a severe muscular degenerative disease. Engineered nucleases TALEN and CRISPR were successfully used to edit the genome of iPS cells generated from DMD patient skin cells, resulting in the disappearance of the mutation responsible for DMD.
The study found that statins promote bone growth in mice with achondroplasia symptoms by rescuing degraded cartilage and increasing chondrocyte proliferation. Statin treatment also accelerated the degradation of the FGFR3 protein, a key factor in skeletal dysplasia.
A Kyoto University research team developed a method to produce erythrocyte progenitor cells with almost unlimited replication ability in vitro. These cells were successfully differentiated into mature erythrocytes with oxygen-carrying capacity, showing potential for a reliable transfusion system.
Researchers at Kyoto University successfully induced direct conversion of human dermal fibroblasts into induced chondrogenic cells, displaying the gene pattern of chondrocytes. Transplanted cells generated hyaline cartilage tissue in immunodeficient mice without forming tumors.
Researchers used cynomolgus monkeys to compare autologous and allogeneic transplantation of iPS cell-derived neural cells. Autologous transplantation produced almost no immune reaction, while allogeneic transplantation provoked an immune response.
Researchers used iPS cells from a CAMT patient to study the disease, finding that thrombopoietin receptor signaling is crucial for megakaryocyte and erythrocyte production. Compensatory transduction of receptors normalized these processes, highlighting the potential for thrombopoietin-like drugs to treat anemia.
Using both familial and sporadic AD iPSCs, the researchers discovered that pathogenesis differed between individual AD patients. They found stress phenotypes associated with intracellular amyloid beta oligomers and attenuated these phenotypes with docosahexaenoic acid (DHA) treatment.
Researchers developed an efficient method to induce human induced pluripotent stem (iPS) cells into intermediate mesoderm, the precursor of kidney cells. The protocol achieved a high success rate of 90% or more and successfully generated renal tubule structures.
Researchers at Kyoto University's Center for iPS Cell Research and Application have successfully recreated ALS-associated abnormalities in motor neurons derived from patients' induced pluripotent stem cells. Anacardic acid was found to rescue certain ALS phenotypes in vitro, offering a promising lead for developing new drug treatments.